Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 5.1% in January

Assertio Holdings, Inc. (NASDAQ:ASRT) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 5,730,000 shares, a decline of 5.1% from the January 15th total of 6,040,000 shares. Based on an average daily volume of 754,900 shares, the short-interest ratio is presently 7.6 days.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. StockNews.com raised Assertio from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Assertio in a report on Monday, December 16th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Captrust Financial Advisors purchased a new stake in Assertio during the third quarter worth $26,000. Stifel Financial Corp purchased a new stake in shares of Assertio in the fourth quarter valued at $27,000. Commonwealth Equity Services LLC purchased a new stake in shares of Assertio in the fourth quarter valued at $30,000. Sonora Investment Management Group LLC purchased a new stake in shares of Assertio in the fourth quarter valued at $39,000. Finally, Wealthfront Advisers LLC purchased a new stake in shares of Assertio in the fourth quarter valued at $53,000. Institutional investors and hedge funds own 48.96% of the company’s stock.

Assertio Trading Down 3.5 %

Shares of ASRT stock opened at $0.81 on Wednesday. The business’s fifty day moving average price is $0.85 and its 200 day moving average price is $1.02. Assertio has a 1-year low of $0.73 and a 1-year high of $1.80. The firm has a market capitalization of $77.51 million, a PE ratio of -1.11, a P/E/G ratio of 3.23 and a beta of 0.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.